Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 10/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12555515 | 0.83 | GSK3B (0.38) | GPR35PKMNPSR1RXFP1ALDH1A1 | |
| SCHEMBL12272176 | 0.78 | HSD17B10 (0.44) | PKMNPSR1RXFP1ALDH1A1LMNA | |
| SCHEMBL5104631 | 0.77 | PKM (0.52) | GPR35PKMNPSR1RXFP1ALDH1A1 | |
| SCHEMBL15878596 | 0.77 | GSK3B (0.61) | GPR35PKMNPSR1RXFP1DAO | |
| SCHEMBL4547877 | 0.76 | ALDH1A1 (0.55) | GPR35PKMNPSR1RXFP1ALDH1A1 | |
| SCHEMBL9836065 | 0.74 | PKM (0.48) | GPR35PKMNPSR1RXFP1ALDH1A1 | |
| SCHEMBL12104573 | 0.74 | PKM (0.48) | GPR35PKMNPSR1RXFP1ALDH1A1 | |
| SCHEMBL6592873 | 0.74 | RXFP1 (0.48) | GPR35PKMNPSR1RXFP1ALDH1A1 | |
| SCHEMBL27416028 | 0.74 | GPR35 (0.40) | GPR35PKMNPSR1RXFP1ALDH1A1 | |
| SCHEMBL28291584 | 0.74 | PKM (0.53) | GPR35PKMNPSR1RXFP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-101646427-B | Inhibitors of akt activity | SMITHKLINE BEECHAM CORP US | 2013-06-12 | — | — | CN | disclosed |
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| CN-1259307-C | Acylated indanyl amines and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2006-06-14 | — | — | CN | disclosed |
| CN-1491207-A | Acylated indanyl amines and their use as pharmaceuticals | ������ҽҩ�¹�����˾ | 2004-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | PPARD, PPARG, PPARA | GPR35 173/4885PKM 566/4885NPSR1 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.